Cisplatin and electrolyte abnormalities
WebIn patients with gynecologic cancers, treated with cisplatin or cisplatin in combination with paclitaxel, a higher incidence of nephrotoxicity in the combination group was noted. 414 In addition, ... Electrolyte abnormalities that may either increase the toxicity of concomitant agents (hypokalemia in patients receiving digoxin) or may be ... WebMay 24, 2006 · Conclusion: Cisplatin can cause permanent nephrotoxicity, including Gitelman-like syndrome. This drug should be considered among the possible causes of chronic unexplained electrolyte disorders. Publication types Case Reports Review MeSH terms Adult Alkalosis / chemically induced* Antineoplastic Agents / adverse effects*
Cisplatin and electrolyte abnormalities
Did you know?
WebCisplatin is a coordinate metal complex with significant antineoplastic activity and various effects, including acute anc chronic renal insufficiency and renal magnesium wasting. … WebMay 24, 2006 · This drug should be considered among the possible causes of chronic unexplained electrolyte disorders. Cisplatin is a well-known nephrotoxic antineoplastic …
WebJul 20, 2024 · Platinum chemotherapy, particularly cisplatin, is commonly associated with electrolyte imbalances, including hypomagnesemia, … http://www.ejmanager.com/mnstemps/93/93-1446132625.pdf#:~:text=The%20most%20common%20electrolyte%20abnormality%20associated%20with%20cisplatin,the%20incidence%20of%20which%20varies%20significantly%20between%20studies.
WebMay 7, 2024 · For the approximately 30% of patients with SCLC who have limited-stage disease at the time of diagnosis (ie, tumors confined to the hemithorax of origin, the … Web• Hypomagnesemia and Accompanying Electrolyte Abnormalities: Monitor during treatment and for at least 8 weeks following the completion. Replete electrolytes as necessary. (5.6) ... and Cisplatin . 5.6 Hypomagnesemia and Accompanying Electrolyte Abnormalities . 5.7 Increased Tumor Progression, Increased Mortality, or Lack ...
WebAug 18, 2024 · Mannitol, given as a hypertonic solution, is primarily used in the treatment of cerebral edema and glaucoma. Although generally well tolerated, a variety of fluid, electrolyte, and kidney complications can occur if the patient is not carefully monitored. (See "Evaluation and management of elevated intracranial pressure in adults", section on ...
Webelectrolyte imbalance (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia ... (with abnormalities of the fasting and 2-hour postprandial sugar) have been observed, and rarely, precipitation of diabetes mellitus has been reported. ... There is a risk of ototoxic effects if cisplatin and LASIX are given concomitantly. In addition, eapg capitol at washington gobletWebNov 1, 2024 · Platinum chemotherapy, particularly cisplatin, is commonly associated with electrolyte imbalances, including hypomagnesemia, hypokalemia, hypophosphatemia, hypocalcemia and hyponatremia. eapg children\u0027s dishesWebSep 1, 2024 · Cisplatin for injectioncan cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug. Neurologic symptoms have … eapg celery vasesWebcisplatin (Rx) Brand and Other Names: Classes: Antineoplastics, Alkylating; Antineoplastics, Platinum Analog Print Dosing & Uses AdultPediatricGeriatric Dosage … eapg celery vaseWebJun 24, 2024 · Cisplatin-induced nephrotoxicity mainly manifests as kidney tubular injury leading to electrolyte disturbances manifested as hypomagnesemia, hypokalemia, and hypophosphatemia and/or increased serum creatinine (occurring more than 7 days after treatment initiation) and decreased glomerular filtration rate [ 8, 9 ]. ea pga tour ps5WebJan 17, 2015 · In this research, we focused only on electrolyte abnormalities following cisplatin toxicity, to predict electrolyte abnormalities occurred in dogs treated with cisplatin. The present study was carried out to evaluate renal function of dogs administered with cisplatin 0.75 mg/kg/day for 5 consecutive days with assaying of electrolytes and … eapg crystalWebFrequent grade 3 or 4 adverse events included fatigue, dyspnea, leukopenia, thrombocytopenia, and electrolyte abnormalities. No objective responses were observed; 5 (50%) of 10 patients treated at the MTD had stable disease. Pharmacokinetics indicated an oral triapine bioavailability of 88%. eapg diamond optic